Locally advanced or metastatic non-small cell lung cancer (NSCLC), Locally advanced or metastatic urothelial carcinoma, Unresectable or metastatic melanoma, Untreated recurrent/metastatic head & neck sqamous cell carcinoma (HNSCC)
Conditions
Brief summary
Objective response rate (ORR) according to RECIST, assessed at least 8 weeks after CIRT, Toxicity according to CTCAE version 5.0
Detailed description
progression-free survival (PFS), overall survival (OS), objective response rate (ORR) according to irRECIST, percentage of patients with disease progression as best response, objective response of the metastatic lesion treated with CIRT, disease control rate (DCR) according to RECIST, defined as ORR+SD
Interventions
DRUGPEMBROLIZUMAB
DRUGATEZOLIZUMAB
DRUGNIVOLUMAB
DRUGCEMIPLIMAB
Sponsors
Fondazione Centro Nazionale Di Adroterapia Oncologica
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR) according to RECIST, assessed at least 8 weeks after CIRT, Toxicity according to CTCAE version 5.0 | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival (PFS), overall survival (OS), objective response rate (ORR) according to irRECIST, percentage of patients with disease progression as best response, objective response of the metastatic lesion treated with CIRT, disease control rate (DCR) according to RECIST, defined as ORR+SD | — |
Countries
Italy
Outcome results
None listed